AveXis

E564274

AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.

Try in SPARQL Jump to: Surface forms Statements Referenced by

Observed surface forms (3)

Statements (44)

Predicate Object
instanceOf biotechnology company
gene therapy
acquiredBy Novartis NERFINISHED
acquisitionDate 2018
acquisitionValue 8770000000 USD
approvalDate 2019
2019
approvedBy U.S. Food and Drug Administration NERFINISHED
U.S. Food and Drug Administration NERFINISHED
changedNameTo Novartis Gene Therapies NERFINISHED
chiefExecutiveOfficer Sean Nolan NERFINISHED
clinicalTrialPhase Phase 3 (for SMA gene therapy prior to approval)
collaboratedWith Nationwide Children’s Hospital NERFINISHED
country United States of America
surface form: United States
developed Zolgensma NERFINISHED
onasemnogene abeparvovec NERFINISHED
focusesOn neuromuscular disorders
rare diseases
spinal muscular atrophy
formerName Biolife Cell Bank NERFINISHED
foundedBy Brian Kaspar NERFINISHED
John Carbona NERFINISHED
Sean Nolan NERFINISHED
headquartersLocation Bannockburn, Illinois NERFINISHED
indication spinal muscular atrophy
spinal muscular atrophy
industry biotechnology
gene therapy
listedOn NASDAQ
parentOrganization Novartis NERFINISHED
Novartis NERFINISHED
product Zolgensma NERFINISHED
onasemnogene abeparvovec NERFINISHED
receivedApprovalFor onasemnogene abeparvovec NERFINISHED
regulatoryApproval U.S. Food and Drug Administration NERFINISHED
researchFocus central nervous system disorders
genetic neuromuscular diseases
specializesIn AAV-based gene therapies
status subsidiary of Novartis
technology adeno-associated virus vector
therapeuticArea gene replacement therapy
tickerSymbol AVXS NERFINISHED
tradeName Zolgensma NERFINISHED
usesVector AAV9 NERFINISHED

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.